For the Inventor, By the Inventor

Enter assignee name

Hyderabad Telangana, India

Laurus Labs Private Limited

USPTO Granted Patents = 66

% Expired Patents = 39.4

EPO Patents = 27

Forward Citations = 81

Loading Chart...

Loading Chart...

108 inventors (with patents filed for the assignee):

Satyanarayana Chava (33 out of 36 patents)

Venkata Sunil Kumar Indukuri (26 out of 26 patents)

Ravindra Babu Bollu (12 out of 12 patents)

4. Ram Thaimattam (12 out of 14 patents)

5. Seeta Ramanjaneyulu Gorantla (10 out of 16 patents)

6. Uma Maheswer Rao Vasireddi (9 out of 9 patents)

7. Uma Maheswar Rao Vasireddi (9 out of 9 patents)

8. Seeta Rama Anjaneyulu Gorantla (9 out of 9 patents)

9. Sanjay Kumar Dehury (9 out of 10 patents)

10. Kameswar Rao Chivukula (9 out of 9 patents)

11. Srihari Raju Kalidindi (8 out of 8 patents)

12. Venkata Lakshmi Narasimha Rao Dammalapati (7 out of 12 patents)

13. Venkata S Indukuri (7 out of 7 patents)

14. Seeta Raman Gorantla (7 out of 7 patents)

15. Sivarami Reddy Yasam (6 out of 6 patents)

Core Competencies:

Tezacaftor

Bictegravir

Dapagliflozin

Nilotinib

Ivacaftor

SGLT2 Inhibitors

Pazopanib

Darunavir

Enzalutamide

Carfilzomib

Polymorphs

Tenofovir

66 patents: Sort by Forward Citations

1. 12630513 - Process for the preparation of trigonelline or pharmaceutically acceptable salts thereof (2026-05-19),

2. 12577236 - Processes for preparation of Tezacaftor (2026-03-17),

3. 12486286 - Process and polymorphic forms of bictegravir and its pharmaceutically acceptable salts or co-crystals thereof (2025-12-02),

4. 12071418 - Processes for preparation of dapagliflozin or its solvates or co-crystals thereof (2024-08-27),

5. 12065426 - Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same (2024-08-20),

6. 11634431 - Process for purification of protected polycyclic carbamoylpyridone derivatives (2023-04-25),

7. 11434196 - Process for preparation of 2-Amino-5-hydroxy propiophenone (2022-09-06),

8. 11427570 - Process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof (2022-08-30),

9. 11427555 - Processes for preparation of dapagliflozin or its solvates or co-crystals thereof (2022-08-30),

10. 11414386 - Process for the preparation of ivacaftor and its intermediates (2022-08-16),

11. 11345685 - Process and crystalline forms of lumacaftor (2022-05-31),

12. 11345684 - Process and crystalline forms of Lumacaftor (2022-05-31),

13. 11318116 - Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof (2022-05-03),

14. 11299477 - Process for the preparation of Pazopanib or a pharmaceutically acceptable salt thereof (2022-04-12),

15. 11066368 - Process for the preparation and particle size reduction of pirfenidone (2021-07-20),

Laurus Labs Private Limited is a leading research-driven pharmaceutical company headquartered in Hyderabad, India. With a strong focus on innovation, quality, and sustainability, Laurus Labs specializes in the development, production, and marketing of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. With a diverse portfolio of over 200 products, Laurus Labs caters to various therapeutic segments, including antiretrovirals, oncology, cardiovascular, central nervous system, and more. The company is committed to improving global healthcare outcomes through its cost-effective and high-quality pharmaceutical products.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Laurus Labs Private Limited

66 Patents

#1 in Hyderabad Telangana

#28 in India

#11,140 in the World

Hyderabad Telangana, India

Laurus Labs Private Limited

Forward Citations = 81

108 inventors:

Satyanarayana Chava (33 out of 36 patents)

Venkata Sunil Kumar Indukuri (26 out of 26 patents)

Ravindra Babu Bollu (12 out of 12 patents)

4. Ram Thaimattam (12 out of 14 patents)

5. Seeta Ramanjaneyulu Gorantla (10 out of 16 patents)

Please report any incorrect information to [email protected]

Loading…